News

10-07-2022

IPRC has been inspected by the USFDA for the seventh time

IPRC has been inspected by the USFDA for the seventh time. The inspection was closed with no observations (no 483 Form was issued). (July. 2022).
>> Read More
26-06-2022

Successful WHO inspection for the second time

Successful WHO inspection for the second timeWe are proud  that IPRC has been inspected successfully for the second time by WHO during June 2022. No critical findings.
>> Read More
01-06-2022

IPRC organizes The 4th MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution

IPRC proud to announce for The 4th MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution on September 19th and 20th 2022, Amman, JordanFollowing on from the remarkable success of the 1st , 2nd and 3rd ...
>> Read More
05-10-2021

IPRC new clinical site gains Jordan FDA approval

Jordan FDA has approved IPRC's new clinical site furnished with 90 beds. This will allow IPRC to double its capacity granting 6 simultaneous studies up to 30 subjects each or one single study up to 180 subjects at the same time. The new ...
>> Read More
04-01-2021

IPRC has acquired two SCIEX 7500 Triple Quad-QTRAP mass detectors

IPRC has acquired two of the newest SCIEX Triple Quad -QTRAP mass detectors. The two “state of the art”, top of line Triple 7500 detectors are intended to increase the productivity of IPRC’s Phase I clinical trials unit while ...
>> Read More
30-12-2020

IPRC goes green

IPRC has announced today the inauguration of its solar plant intended as a promise of clean, affordable and renewable solar energy. The plant will supply our facilities with its power needs with solar energy. This clean power project is ...
>> Read More
21-08-2019

IPRC's Clinical Sites

IPRC has obtained the JFDA accreditation for a third clinical site with a capacity of 30 beds. This will promote the capacity of IPRC's clinical sites to 90 beds. 
>> Read More
22-11-2018

IPRC has been inspected by the USFDA for the sixth time

IPRC has been inspected by the USFDA for the sixth time. The inspection was closed with no observations (no 483 Form was issued). (Oct. 2018). 
>> Read More
09-07-2018

IPRC has been inspected by EMA for the fourth time

IPRC has been inspected successfully by EMA on the 24th to 28th of June, 2018.
>> Read More
27-05-2018

IPRC has acquired two Triple Quad mass detectors of AB SCIEX 6500 plus

IPRC has acquired two of the newest Triple Quad mass detectors of AB SCIEX. The two “state of the art”, top of line Triple Quad 6500+ detectors are intended to increase ...
>> Read More
22-10-2017

Third Mena Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis And Dissolution

Third Mena Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis And DissolutionAmman (Jordan), September 24th and 25th, 2018.Following on from the remarkable success of the 1st and 2nd conferences held in 2013 and 2015, ...
>> Read More
30-12-2016

IPRC has been inspected by the USFDA for the fifth time

IPRC has been inspected by the USFDA for the fifth time. No critical nor major findings.
>> Read More
17-05-2015

Successful WHO inspection

We are proud to announce that IPRC has been inspected successfully by WHO during this last week. No critical nor major findings. The inspectors concluded IPRC is compliant with GCP/GLP. This new inspection adds a new credit to our long ...
>> Read More
16-05-2015

IPRC organizes the 2ed MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis, Dissolution and Biosimilars

Following the remarkable success of the 1st MENA Regulatory Conference on Bioequivalence, Biowaivers, Bioanalysis and Dissolution”, held in Amman in 2013, with more than 300 participants; the International Pharmaceutical Research ...
>> Read More
21-02-2015

New method for Tiotropium determination

IPRC is glad to announce it has developed and validated a very sensitive method to determine Tiotropium in human plasma with LOQ of 0.1 pg/ml. The method has been successfully applied to determinate Tiotropium in human subjects after a ...
>> Read More